AKTX
Akari Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$9.66
+18.09%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$9.01
From 52W high−70.55%
Volume78666.00
Market cap$22.07M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$9.01
From 52W high
−70.55%
Volume
78666.00
Market cap
$22.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
50.1
MomentumView details →
1D Return
+18.09%
YTD Return
−22.58%
SummaryUpdated Jun 1, 2026
Akari Therapeutics, Plc (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company founded in 2014 and based in London, United Kingdom. The company specializes in developing advanced therapies targeting autoimmune and inflammatory diseases through complement system inhibition. Since its IPO in January 2014, Akari has focused its research and development efforts on creating treatments for rare and serious conditions where the complement system - a key component of the immune system - plays a destructive role. The company is currently in clinical development phases with its lead drug candidate and has not yet generated commercial revenue.
Similar companies
Latest newsMore news →
Akari Therapeutics Plc appointed Abizer Gaslightwala as Chief Executive Officer effective August 18, 2026, with a base salary of $625,000 and a 55% bonus target.18d agoAkari Therapeutics announced that AKTX-101, its antibody-drug conjugate, demonstrated robust anti-tumor activity in preclinical urothelial cancer models, supporting its differentiated ADC strategy.63d ago